Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16595926rdf:typepubmed:Citationlld:pubmed
pubmed-article:16595926lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C0699790lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C0282639lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C1518174lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C0042287lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C0013081lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C1415761lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C1708295lld:lifeskim
pubmed-article:16595926lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:16595926pubmed:issue4lld:pubmed
pubmed-article:16595926pubmed:dateCreated2006-4-5lld:pubmed
pubmed-article:16595926pubmed:abstractTextGlucose deprivation is a fundamental feature of poorly vascularized solid tumors and leads to activation of the molecular chaperone GRP78, which is associated with the unfolded protein response (UPR), a stress-signaling pathway, in tumor cells. We recently isolated an active compound, M126, that inhibits transcription from a GRP78 promoter reporter construct. M126 was identified as valinomycin by various spectroscopic methods. We found that valinomycin prevents UPR-induced protein expression, such as GRP78 and GRP94. The GRPs-inhibitory action of valinomycin severe hypoglycemic and results in selective cell death of the stressed cancer cells. Our findings demonstrate that GRP78 may be an excellent target for the use of cancer chemotherapy in the treatment of solid tumors.lld:pubmed
pubmed-article:16595926pubmed:languageenglld:pubmed
pubmed-article:16595926pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:citationSubsetIMlld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16595926pubmed:statusMEDLINElld:pubmed
pubmed-article:16595926pubmed:monthAprlld:pubmed
pubmed-article:16595926pubmed:issn0918-6158lld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:Shin-YaKazuoKlld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:YooIck-DongIDlld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:ParkYoung-Min...lld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:BaeKi-HwanKHlld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:RyooIn-JaIJlld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:ParkHae-Ryong...lld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:ChooSoo-JinSJlld:pubmed
pubmed-article:16595926pubmed:authorpubmed-author:HwangJi-HwanJ...lld:pubmed
pubmed-article:16595926pubmed:issnTypePrintlld:pubmed
pubmed-article:16595926pubmed:volume29lld:pubmed
pubmed-article:16595926pubmed:ownerNLMlld:pubmed
pubmed-article:16595926pubmed:authorsCompleteYlld:pubmed
pubmed-article:16595926pubmed:pagination817-20lld:pubmed
pubmed-article:16595926pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:meshHeadingpubmed-meshheading:16595926...lld:pubmed
pubmed-article:16595926pubmed:year2006lld:pubmed
pubmed-article:16595926pubmed:articleTitleSelective cytotoxic activity of valinomycin against HT-29 Human colon carcinoma cells via down-regulation of GRP78.lld:pubmed
pubmed-article:16595926pubmed:affiliationLaboratory of Antioxidant, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea.lld:pubmed
pubmed-article:16595926pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16595926pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16595926lld:pubmed